



Topiramate Extended-Release Capsules

Type of Posting	Revision Bulletin
Posting Date	31-Jan-2025
Official Date	1-Feb-2025
Expert Committee	Small Molecules 4

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 4 Expert Committee has revised the Topiramate Extended-Release Capsules monograph. The purpose of this revision is to add *Dissolution Test 3* and *Dissolution Test 4* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s). The revision also necessitates a change in the table numbering in the tests for *Limit of Sulfamate and Sulfate* and *Organic Impurities*.

- *Dissolution Test 3* was validated using the Inertsil ODS-3 brand of column with L1 packing. The typical retention time for topiramate is about 4 min.
- *Dissolution Test 4* was validated using the Inertsil ODS-3 brand of column with L1 packing. The typical retention time for topiramate is about 6 min.

The Topiramate Extended-Release Capsules Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact V. Durga Prasad, Senior Scientist II (91-40-4448-8723 or durgaprasad.v@usp.org).